Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas F Brown

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|August 3, 2016
Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman PrimatesSteven M Weldon, Matthew A Cerny, Kristina Gueneva-Boucheva, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|August 1, 2017
Impact of Aldosterone Synthase Inhibitor FAD286 on Steroid Hormone Profile in Human Adrenocortical CellsCoy Brunssen, Anja Hofmann, Mirko Peitzsch, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 29, 2025
Pharmacodynamic effects of highly selective aldosterone synthase inhibitor vicadrostat in cynomolgus monkeys: Contrasting effects of once versus twice daily dosingSteven M Weldon, Derek A Cogan, Matthew A Cerny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib StudyMagnus T Dillon, Lorna Grove, Kate L Newbold, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Identification of an Adamantyl Azaquinolone JNK Selective InhibitorNancy-Ellen Haynes, Nathan R Scott, Li C Chen, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|April 21, 2017
The Aldosterone Synthase Inhibitor FAD286 is Suitable for Lowering Aldosterone Levels in ZDF Rats but not in db/db MiceAnja Hofmann, Coy Brunssen, Mirko Peitzsch, et al.
Endocrinology|August 16, 2016
Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) RatsAnja Hofmann, Coy Brunssen, Mirko Peitzsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2021
CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal AdenocarcinomaDeepak Raj, Maria Nikolaidi, Irene Garces, et al.
Neuro-Oncology Advances|August 13, 2025
Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trialNicholas F Brown, Catherine McBain, Lucy Brazil, et al.
Neuro-Oncology|May 23, 2018
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098Nicholas F Brown, Matthew Williams, Hendrik-Tobias Arkenau, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Pharmacology and Experimental Therapeutics|August 3, 2016
Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman PrimatesSteven M Weldon, Matthew A Cerny, Kristina Gueneva-Boucheva, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|August 1, 2017
Impact of Aldosterone Synthase Inhibitor FAD286 on Steroid Hormone Profile in Human Adrenocortical CellsCoy Brunssen, Anja Hofmann, Mirko Peitzsch, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 29, 2025
Pharmacodynamic effects of highly selective aldosterone synthase inhibitor vicadrostat in cynomolgus monkeys: Contrasting effects of once versus twice daily dosingSteven M Weldon, Derek A Cogan, Matthew A Cerny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib StudyMagnus T Dillon, Lorna Grove, Kate L Newbold, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Identification of an Adamantyl Azaquinolone JNK Selective InhibitorNancy-Ellen Haynes, Nathan R Scott, Li C Chen, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|April 21, 2017
The Aldosterone Synthase Inhibitor FAD286 is Suitable for Lowering Aldosterone Levels in ZDF Rats but not in db/db MiceAnja Hofmann, Coy Brunssen, Mirko Peitzsch, et al.
Endocrinology|August 16, 2016
Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) RatsAnja Hofmann, Coy Brunssen, Mirko Peitzsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2021
CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal AdenocarcinomaDeepak Raj, Maria Nikolaidi, Irene Garces, et al.
Neuro-Oncology Advances|August 13, 2025
Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trialNicholas F Brown, Catherine McBain, Lucy Brazil, et al.
Neuro-Oncology|May 23, 2018
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098Nicholas F Brown, Matthew Williams, Hendrik-Tobias Arkenau, et al.
Pageof 4